BioAffinity Closes $3.2M Offering, Securing Critical Funding Amid Going Concern Warning
BIAF sits 21% above its 52-week low of $0.693 on light trading volume (0.4× avg).
Summary
BioAffinity Technologies has successfully closed a $3.2 million public offering of common stock and pre-funded warrants. This critical financing directly addresses the company's urgent liquidity needs, as highlighted in its Q1 10-Q filing which warned of a cash runway only extending through June 2026 and a going concern. The offering, previously detailed in S-1 and 424B4 filings, provides essential working capital to extend the company's operational runway. While highly dilutive given the company's small market capitalization, this capital raise is crucial for the company's immediate survival.
At the time of this announcement, BIAF was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.69 to $13.80. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.